Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Nonradiographic Axial Spondyloarthritis Topic Center

Featured Article

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Earlier Treatment May Improve Outcomes in Patients With Nonradiographic Axial Spondyloarthritis
10/14/2022
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs...
10/14/2022
First Report Managed Care

Newsfeed

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement